Asthma Medication Receives New Warning

• Autores: Diane S. Aschenbrenner
• Localización: American Journal of Nursing, ISSN 0002-936X, Vol. 115, Nº. 1, 2015, págs. 22-23
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • * The labeling of omalizumab (Xolair), a drug used to treat allergic asthma, now carries a warning that its use may slightly increase the risk of cardiovascular complications. The drug may also pose an increased risk of inducing cancer.